Adams Diversified Equity Fund’s Supernus Pharmaceuticals SUPN Stock Holding History

Adams Diversified Equity Fund’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,700	Closed	-$89K	–	184
2019 Q2	$89K	Sell	2,700 -3,000	-53%	-$103K	﹤0.01%	212
2019 Q1	$200K	Buy	+5,700	New	+$212K	0.01%	203
2018 Q1	–	Sell	-14,200	Closed	-$566K	–	226
2017 Q4	$566K	Sell	14,200 -4,200	-23%	-$166K	0.03%	190
2017 Q3	$736K	Sell	18,400 -700	-4%	-$30.3K	0.04%	197
2017 Q2	$823K	Buy	+19,100	New	+$680K	0.05%	169

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Adams Diversified Equity Fund's SUPN Position: Q3 2019 in Review

Adams Diversified Equity Fund sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 2,700 shares — an estimated $89K sold.

Adams Diversified Equity Fund first reported a position in SUPN in Q2 2017 and held it in 5 quarters. The position peaked at $823K in Q2 2017. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Adams Diversified Equity Fund reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Adams Diversified Equity Fund sold 2,700 Supernus Pharmaceuticals shares in Q3 2019, an estimated $89K.
Adams Diversified Equity Fund first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 5 quarters.
Adams Diversified Equity Fund's Supernus Pharmaceuticals position peaked at $823K in Q2 2017.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Adams Diversified Equity Fund's 13F filing for Q3 2019, filed 28 Oct 2019.